17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development

Journal of Steroid Biochemistry and Molecular Biology

Volumn 125, Issue 1-2, 2011, Pages 66-82

  Marchais Oberwinkler, Sandrine ^a   Henn, Claudia ^a,b   Möller, Gabriele ^c   Klein, Tobias ^a,b   Negri, Matthias ^a,b   Oster, Alexander ^a   Spadaro, Alessandro ^d   Werth, Ruth ^a   Wetzel, Marie ^a   Xu, Kuiying ^a   Frotscher, Martin ^a   Hartmann, Rolf W ^a,b   Adamski, Jerzy ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d ElexoPharm GmbH   (Germany)

Author keywords

17 Hydroxysteroid dehydrogenases; Animal models; Inhibitors; Protein structures; Therapeutic targets

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; ESTROGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; CATALYSIS; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG EFFICACY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HUMAN; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; OVARY TUMOR; PROSTATE CANCER; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; REVIEW; SEQUENCE ANALYSIS; STEROID HYDROXYLATION; STEROID THERAPY; STEROIDOGENESIS; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; TREATMENT RESPONSE; UTERUS MYOMA;

17-HYDROXYSTEROID DEHYDROGENASES; AMINO ACID SEQUENCE; ANDROGENS; ANIMALS; BREAST NEOPLASMS; CATALYTIC DOMAIN; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; ISOENZYMES; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PHYLOGENY; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

ANIMALIA; MAMMALIA;

EID: 79955776935     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.12.013     Document Type: Review

References (145)

1. F. Hoffmann, and E. Maser Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily Drug Metab. Rev. 39 1 2007 87 144
2. T. Matsunaga, S. Shintani, and A. Hara Multiplicity of mammalian reductases for xenobiotic carbonyl compounds Drug Metab. Pharmacokinet. 21 1 2006 1 18
3. E. Maser Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases Biochem. Pharmacol. 49 4 1995 421 440
4. C. Labrie, A. Bélanger, and F. Labrie Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate Endocrinology 123 3 1988 1412 1417
5. F. Labrie Intracrinology Mol. Cell. Endocrinol. 78 3 1991 C113 C118
6. T.M. Penning Molecular endocrinology of hydroxysteroid dehydrogenases Endocr. Rev. 18 3 1997 281 305 (Pubitemid 27246879)
7. W.L. Duax, D. Ghosh, and V. Pletnev Steroid dehydrogenase structures, mechanism of action, and disease Vitam. Horm. 58 2000 121 148
8. E.R. Prossnitz, and M. Maggiolini Non-genomic signaling by steroids Mol. Cell. Endocrinol. 308 1-2 2009 1 2
9. C.M. Revankar, D.F. Cimino, L.A. Sklar, J.B. Arterburn, and E.R. Prossnitz A transmembrane intracellular estrogen receptor mediates rapid cell signaling Science 307 2005 1625 1630 (Pubitemid 40354745)
10. F. Labrie, V. Luu-The, S.X. Lin, J. Simard, C. Labrie, M. El-Alfy, G. Pelletier, and A. Bélanger Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease J. Mol. Endocrinol. 25 1 2000 1 16 (Pubitemid 30618058)
11. T.M. Penning Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action Hum. Reprod. Update 9 3 2003 193 205 (Pubitemid 36827058)
12. S. Gobbi, A. Cavalli, A. Rampa, F. Belluti, L. Piazzi, A. Paluszcak, R.W. Hartmann, M. Recanatini, and A. Bisi Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme J. Med. Chem. 49 15 2006 4777 4780 (Pubitemid 44162705)
13. D. Schuster, C. Laggner, T.M. Steindl, A. Palusczak, R.W. Hartmann, and T. Langer Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors J. Chem. Inf. Model. 46 3 2006 1301 1311 (Pubitemid 43999173)
14. F. Leonetti, A. Favia, A. Rao, R. Aliano, A. Paluszcak, R.W. Hartmann, and A. Carotti Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors J. Med. Chem. 47 27 2004 6792 6803 (Pubitemid 40053767)
15. M. Le Borgne, P. Marchand, B. Delevoye-Seiller, J.M. Robert, G. Le Baut, R.W. Hartmann, and M. Palzer New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles Bioorg. Med. Chem. Lett. 9 3 1999 333 336 (Pubitemid 29084489)
16. M. Le Borgne, P. Marchand, M. Duflos, B. Delevoye-Seiller, S. Piessard-Robert, G. Le Baut, R.W. Hartmann, and M. Palzer Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1H-indoles and 3-(1-azolyl-1-phenylmethyl)-1H- indoles as inhibitors of P450 arom Arch. Pharm. 330 5 1997 141 145 (Pubitemid 27298759)
17. E. Baston, and R.W. Hartmann N-substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory activity Bioorg. Med. Chem. Lett. 9 11 1999 1601 1606 (Pubitemid 29274205)
18. W. Reichert, J. Jose, and R.W. Hartmann 5 alpha-reductase in intact DU145 cells: evidence for isozyme I and evaluation of novel inhibitors Arch. Pharm. 333 7 2000 201 204
19. F. Picard, E. Baston, W. Reichert, and R.W. Hartmann Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2 Bioorg. Med. Chem. 8 6 2000 1479 1487 (Pubitemid 30398467)
20. E. Baston, O.I. Salem, and R.W. Hartmann 6-Substituted 3,4-dihydro-naphthalene-2-carboxylic acids: synthesis and structure-activity studies in a novel class of human 5alpha reductase inhibitors J. Enzyme Inhib. Med. Chem. 17 5 2002 303 320 (Pubitemid 35469531)
21. S. Aggarwal, S. Thareja, A. Verma, T.R. Bhardwaj, and M. Kumar An overview on 5alpha-reductase inhibitors Steroids 75 2 2010 109 153
22. F. Picard, T. Schulz, and R.W. Hartmann 5-Phenyl substituted 1-methyl-2-pyridones and 4′-substituted biphenyl-4-carboxylic acids. Synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2 Bioorg. Med. Chem. 10 2 2002 437 448 (Pubitemid 33121268)
23. C. Prehn, G. Möller, and J. Adamski Recent advances in 17beta-hydroxysteroid dehydrogenases J. Steroid Biochem. Mol. Biol. 114 1-2 2009 72 77
24. T.M. Penning, and M.C. Byrns Steroid hormone transforming aldo-keto reductases and cancer Ann. N.Y. Acad. Sci. 1155 2009 33 42
25. B. Persson, Y. Kallberg, J.E. Bray, E. Bruford, S.L. Dellaporta, A.D. Favia, R.G. Duarte, H. Jörnvall, K.L. Kavanagh, N. Kedishvili, M. Kisiela, E. Maser, R. Mindnich, S. Orchard, T.M. Penning, J.M. Thornton, J. Adamski, and U. Oppermann The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative Chem. Biol. Interact. 178 1-3 2009 94 98
26. G. Möller, and J. Adamski Integrated view on 17beta-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 301 1-2 2009 7 19
27. V. Luu-The Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase J. Steroid Biochem. Mol. Biol. 76 1-5 2001 143 151 (Pubitemid 32510676)
28. M. Meier, G. Möller, and J. Adamski Perspectives in understanding the role of human 17beta-hydroxysteroid dehydrogenases in health and disease Ann. N.Y. Acad. Sci. 1155 2009 15 24
29. P. Lukacik, B. Keller, G. Bunkoczi, K.L. Kavanagh, W.H. Lee, J. Adamski, and U. Oppermann Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity Biochem. J. 402 3 2007 419 427 (Pubitemid 46423879)
30. F. Haller, E. Moman, R.W. Hartmann, J. Adamski, and R. Mindnich Molecular framework of steroid/retinoid discrimination in 17beta-hydroxysteroid dehydrogenase type 1 and photoreceptor-associated retinol dehydrogenase J. Mol. Biol. 399 2010 255 267
31. S. Zhongyi, P. Rantakari, T. Lamminen, J. Toppari, and M. Poutanen Transgenic male mice expressing human hydroxysteroid dehydrogenase 2 indicate a role for the enzyme independent of its action on sex steroids Endocrinology 148 8 2007 3827 3836 (Pubitemid 47105876)
32. P. Lukacik, K.L. Kavanagh, and U. Oppermann Structure and function of human 17beta-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 248 1-2 2006 61 71
33. Y. Miyoshi, A. Ando, E. Shiba, T. Taguchi, Y. Tamaki, and S. Noguchi Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers Int. J. Cancer 94 5 2001 685 689 (Pubitemid 33035688)
34. A. Jansson 17beta-hydroxysteroid dehydrogenase enzymes and breast cancer J. Steroid Biochem. Mol. Biol. 144 1-2 2009 64 67
35. C.H. Blomquist, M. Bonenfant, D.M. McGinley, Z. Posalaky, D.J. Lakatua, S. Tuli-Puri, D.G. Bealka, and Y. Tremblay Androgenic and estrogenic 17beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the type 1, 2 and 5 isoforms J. Steroid Biochem. Mol. Biol. 81 4-5 2002 343 351 (Pubitemid 35282454)
36. T. Šmuc, M. Ribič Pucejl, J. Šinkovec, B. Husen, H. Thole, and T. Lanišnik Rižner Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis Gynecol. Endocrinol. 23 2 2007 105 111 (Pubitemid 46481023)
37. T. Saloniemi, P. Järvensivu, P. Koskimies, H. Jokela, T. Lamminen, S. Ghaem-Maghami, R. Dina, P. Damdimopoulou, S. Mäkelä, A. Perheentupa, H. Kujari, J. Brosens, and M. Poutanen Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice Am. J. Pathol. 176 3 2010 1443 1451
38. T. Kasai, M. Shozu, K. Murakami, T. Segawa, K. Shinohara, K. Nomura, and M. Inoue Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma J. Clin. Endocrinol. Metab. 89 11 2004 5661 5668 (Pubitemid 39518456)
39. D.T. Felson, Y. Zhang, M.T. Hannan, D.P. Kiel, P.W. Wilson, and J.J. Anderson The effect of postmenopausal estrogen therapy on bone density in elderly women N. Engl. J. Med. 329 16 1993 1141 1146 (Pubitemid 23295455)
40. C.L. Chen, N.S. Weiss, P. Newcomb, W. Barlow, and E. White Hormone replacement therapy in relation to breast cancer JAMA 287 6 2002 734 741 (Pubitemid 34250459)
41. C.M. Bagi, J. Wood, D. Wilkie, and B. Dixon Effect of 17beta-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys J. Musculoskelet. Neuronal. Interact. 8 3 2008 267 280
42. E. Koh, T. Noda, J. Kanaya, and M. Namiki Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues Prostate 53 2 2002 154 159
43. S.Y. Yang, X.Y. He, and H. Schulz Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase Trends Endocrinol. Metab. 16 4 2005 167 175 (Pubitemid 40603096)
44. S.D. Yan, J. Fu, C. Soto, X. Chen, H. Zhu, F. Al-Mohanna, K. Collison, A. Zhu, E. Stern, T. Saido, M. Tohyama, S. Ogawa, A. Roher, and D. Stern An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease Nature 389 6652 1997 689 695 (Pubitemid 27458947)
45. U.C. Oppermann, S. Salim, L.O. Tjernberg, L. Terenius, and H. Jörnvall Binding of amyloid beta-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease FEBS Lett. 451 3 1999 238 242 (Pubitemid 29243784)
46. J.W. Lustbader, M. Cirilli, C. Lin, H.W. Xu, K. Takuma, N. Wang, C. Caspersen, X. Chen, S. Pollak, M. Chaney, F. Trinchese, S. Liu, F. Gunn-Moore, L.F. Lue, D.G. Walker, P. Kuppusamy, Z.L. Zewier, O. Arancio, D. Stern, S.S. Yan, and H. Wu ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease Science 304 5669 2004 448 452 (Pubitemid 38495942)
47. C.R. Kissinger, P.A. Rejto, L.A. Pelletier, J.A. Thomson, R.E. Showalter, M.A. Abreo, C.S. Agree, S. Margosiak, J.J. Meng, R.M. Aust, D. Vanderpool, B. Li, A. Tempczyk-Russell, and J.E. Villafranca Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics J. Mol. Biol. 342 3 2004 943 952 (Pubitemid 39165660)
48. D.P. Sherbet, M. Papari-Zareei, N. Khan, K.K. Sharma, A. Brandmaier, S. Rambally, A. Chattopadhyay, S. Andersson, A.K. Agarwal, and R.J. Auchus Cofactors, redox state, and directional preferences of hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 265-266 2007 83 88 (Pubitemid 46273967)
49. M. Buehner, G.C. Ford, D. Moras, K.W. Olsen, and M.G. Rossman d-Glyceraldehyde-3-phosphate dehydrogenase: three-dimensional structure and evolutionary significance Proc. Natl. Acad. Sci. U.S.A. 70 11 1973 3052 3054
50. Y.W. Huang, I. Pineau, H.J. Chang, A. Azzi, V. Bellemare, S. Laberge, and S.X. Lin Critical residues for the specificity of cofactors and substrates in human estrogenic 17beta-hydroxysteroid dehydrogenase 1: variants designed from the three-dimensional structure of the enzyme Mol. Endocrinol. 15 11 2001 2010 2020 (Pubitemid 33022537)
51. B.M. McKeever, B.K. Hawkins, W.M. Geissler, L. Wu, R.P. Sheridan, R.T. Mosley, and S. Andersson Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation/reduction kinetics Biochim. Biophys. Acta 1601 1 2002 29 37 (Pubitemid 38234528)
52. D.P. Sherbet, O.L. Guryev, M. Papari-Zareei, D. Mizrachi, S. Rambally, S. Akbar, and R.J. Auchus Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17beta-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells Endocrinology 150 9 2009 4154 4162
53. P. Lukacik, N. Shafqat, K. Kavanagh, J. Bray, F. Von Delft, A. Edwards, C. Arrowsmith, M. Sundstrom, U. Oppermann, Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 4 in complex with NAD (2010), doi:10.2210/pdb1zbq/pdb.
54. T.M. Penning Molecular determinants of steroid recognition and catalysis in aldo-keto reductases. Lessons from 3alpha-hydroxysteroid dehydrogenase J. Steroid Biochem. Mol. Biol. 69 1-6 1999 211 225 (Pubitemid 29305539)
55. T. Puranen, M. Poutanen, H. Peltoketo, P. Vihko, and R.K. Vihko Site-directed mutagenesis of the putative active site of human 17β-hydroxysteroid dehydrogenase type 1 Biochem. J. 304 1994 289 293 (Pubitemid 24354257)
56. C.C. Hwang, Y.H. Chang, C.N. Hsu, H.H. Hsu, C.W. Li, and H.I. Pon Mechanistic roles of Ser-114, Tyr-155, and Lys-159 in 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase from Comamonas testosteroni J. Biol. Chem. 280 5 2005 3522 3528
57. C. Filling, K.D. Berndt, J. Benach, S. Knapp, T. Prozorovski, E. Nordling, R. Ladenstein, H. Jörnvall, and U. Oppermann Critical residues for structure and catalysis in short-chain dehydrogenases/reductases J. Biol. Chem. 277 28 2002 25677 25684 (Pubitemid 34959957)
58. D. Ghosh, and P. Vihko Molecular mechanisms of estrogen recognition and 17-keto reduction by human 17beta-hydroxysteroid dehydrogenase 1 Chem. Biol. Interact. 130-132 1-3 2001 637 650 (Pubitemid 32295851)
59. K.L. Kavanagh, H. Jörnvall, B. Persson, and U. Oppermann The SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes Cell. Mol. Life Sci. 65 24 2008 3895 3906
60. T.M. Penning, S. Steckelbroeck, D.R. Bauman, M.W. Miller, Y. Jin, D.M. Peehl, K.M. Fung, and H.K. Lin Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors Mol. Cell. Endocrinol. 248 1-2 2006 182 191
61. T. Puranen, M. Poutanen, D. Ghosh, P. Vihko, and R. Vihko Characterization of structural and functional properties of human 17β-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis Mol. Endocrinol. 11 1 1997 77 86 (Pubitemid 27021256)
62. A. Gangloff, R. Shi, V. Nahoum, and S.X. Lin Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17β-hydroxysteroid dehydrogenase FASEB J. 17 2 2003 274 276
63. Q. Han, R.L. Campbell, A. Gangloff, Y.W. Huang, and S.X. Lin Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/c-19 steroid discrimination and enzyme-induced strain J. Biol. Chem. 275 2 2000 1105 1111 (Pubitemid 30051160)
64. A. Azzi, P.H. Rehse, D.W. Zhu, R.L. Campbell, F. Labrie, and S.X. Lin Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol Nat. Struct. Biol. 3 8 1996 665 668 (Pubitemid 26260054)
65. S. Alho-Richmond, A. Lilienkampf, and K. Wähälä Active site analysis of 17β-hydroxysteroid dehydrogenase type 1 enzyme complexes with SPROUT Mol. Cell. Endocrinol. 248 1-2 2006 208 213
66. M. Negri, M. Recanatini, R.W. Hartmann, Dynamic motion investigation of 17β-HSD1 provides insights in its enzyme kinetics and ligand binding, PLoS ONE, 5 (8) (2010): e120026. doi:10.1371/journal.pone0012026.
67. E. Bey, S. Marchais-Oberwinkler, M. Negri, P. Kruchten, A. Oster, T. Klein, A. Spadaro, R. Werth, M. Frotscher, B. Birk, and R.W. Hartmann New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity J. Med. Chem. 52 21 2009 6724 6743
68. L.A. Akinola, M. Poutanen, and R. Vihko Cloning of rat 17 beta-hydroxysteroid dehydrogenase type 2 and characterization of tissue distribution and catalytic activity of rat type 1 and type 2 enzymes Endocrinology 137 5 1996 1572 1579 (Pubitemid 26133927)
69. P. Nokelainen, T. Puranen, H. Peltoketo, M. Orava, P. Vihko, and R. Vihko Molecular cloning of mouse 17β-hydroxysteroid dehydrogenase type 1 and characterization of enzyme activity Eur. J. Biochem. 236 2 1996 482 490 (Pubitemid 26098832)
70. R. Mindnich, F. Haller, F. Halbach, G. Moeller, M. Hrabe de Angelis, and J. Adamski Androgen metabolism via 17β-hydroxysteroid dehydrogenase type 3 in mammalian and non-mammalian vertebrates: comparison of the human and the zebrafish enzyme J. Mol. Endocrinol. 35 2 2005 305 316 (Pubitemid 41556178)
71. P. Kruchten, R. Werth, E. Bey, A. Oster, S. Marchais-Oberwinkler, M. Frotscher, and R.W. Hartmann Selective inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17βHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells J. Steroid Biochem. Mol. Biol. 114 3-5 2009 200 206
72. G. Möller, B. Husen, D. Kowalik, L. Hirvelä, D. Plewczynski, L. Rychlewski, J. Messinger, H. Thole, and J. Adamski Species used for drug testing reveal different inhibition susceptibility for 17beta-hydroxysteroid dehydrogenase type 1 PLoS ONE 5 6 2010 e10969
73. J.A. Sha, K. Dudley, W.R. Rajapaksha, and P.J. O'Shaughnessy Sequence of mouse 17beta-hydroxysteroid dehydrogenase type 3 cDNA and tissue distribution of the type 1 and type 3 isoform mRNAs J. Steroid Biochem. Mol. Biol. 60 1-2 1997 19 24 (Pubitemid 27217239)
74. D. Poirier Inhibitors of 17β-hydroxysteroid dehydrogenases Curr. Med. Chem. 10 6 2003 453 477
75. D. Poirier Advances in development of inhibitors of 17β- hydroxysteroid dehydrogenases Anticancer Agents Med. Chem. 9 6 2009 642 660
76. P. Brožič, T. Lanišnik Rižner, and S. Gobec Inhibitors of 17β-hydroxysteroid dehydrogenase type 1 Curr. Med. Chem. 15 2 2008 137 150
77. J.M. Day, H.J. Tutill, A. Purohit, and M.J. Reed Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer 15 3 2008 665 692
78. J.M. Day, H.J. Tutill, and A. Purohit 17β-Hydroxysteroid dehydrogenase inhibitors Minerva Endocrinol. 35 2 2010 87 108
79. P.J. Michiels, C. Ludwig, M. Stephan, C. Fischer, G. Möller, J. Messinger, M. van Dongen, H. Thole, J. Adamski, and U.L. Günther Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17β-hydroxysteroid dehydrogenase type 1 J. Steroid Biochem. Mol. Biol. 117 4-5 2009 93 98
80. W. Qiu, R.L. Campbell, A. Gangloff, P. Dupuis, R.P. Boivin, M.R. Tremblay, D. Poirier, and S.X. Lin A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity FASEB J. 16 13 2002 1829 1831
81. M. Berube, and D. Poirier Design, chemical synthesis, and in vitro biological evaluation of simplified estradiol-adenosine hybrids as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 Can. J. Chem. 87 2009 1180 1199
82. M. Berube, F. Delagoutte, and D. Poirier Preparation of 6beta-estradiol derivative libraries as bisubstrate inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 using the multidetachable sulfamate linker Molecules 15 3 2010 1590 1631
83. M. Mazumdar, D. Fournier, D.W. Zhu, C. Cadot, D. Poirier, and S.X. Lin Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy Biochem. J. 424 3 2009 357 366
84. F. Rouillard, J. Lefebvre, M.A. Fournier, and D. Poirier Chemical synthesis, 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity and assessment of in vitro and in vivo estrogenic activities of estradiol derivatives Open Enzyme Inhib. J. 1 2008 61 71
85. J. Messinger, B. Husen, U. Schoen, H. Thole, P. Koskimies, M. Unkila, Substituted estratrien derivatives as 17beta HSD inhibitors, WO2008/065100 (2008).
86. J. Messinger, U. Schoen, B. Husen, H. Thole, P. Koskimies, L. Kallio, Therapeutically active triazoles and their use, WO2008/034796 (2008).
87. J. Messinger, B. Husen, P. Koskimies, L. Hirvelä, L. Kallio, P. Saarenketo, and H. Thole Estrone C15 derivatives - a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors Mol. Cell. Endocrinol. 301 1-2 2009 216 224
88. G. Möller, D. Deluca, C. Gege, A. Rosinus, D. Kowalik, O. Peters, P. Droescher, W. Elger, J. Adamski, and A. Hillisch Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and d-homo-estrone Bioorg. Med. Chem. Lett. 19 23 2009 6740 6744
89. D. Schuster, E.M. Maurer, C. Laggner, L.G. Nashev, T. Wilckens, T. Langer, and A. Odermatt The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening J. Med. Chem. 49 12 2006 3454 3466 (Pubitemid 43904337)
90. R.K. Lota, S. Dhanani, C.P. Owen, and S. Ahmed Search for potential non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase (17β-HSD) in the treatment of hormone-dependent cancers Lett. Drug Des. Dis. 4 2007 180 184 (Pubitemid 46474157)
91. M.S. Olusjano, I. Shahid, C.P. Owen, and S. Ahmed Inhibition of 17β-hydroxysteroid dehydrogenase (17β-HSD) by imidazole-based compounds Lett. Drug Des. Dis. 5 2008 48 51 (Pubitemid 351225646)
92. P. Kocbek, K. Teskac, P. Brožič, T. Lanišnik Rižner, S. Gobec, and J. Kristl Effect of free and in poly(η-caprolactone) nanoparticles incorporated new type 1 17beta-hydroxysteroid dehydrogenase inhibitors on cancer cells Curr. Nanosci. 6 2010 69 76
93. G.M. Allan, N. Vicker, H.R. Lawrence, H.J. Tutill, J.M. Day, M. Huchet, E. Ferrandis, M.J. Reed, A. Purohit, and B.V.L. Potter Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design Bioorg. Med. Chem. 16 8 2008 4438 4456 (Pubitemid 351545841)
94. A. Lilienkampf, S. Karkola, S. Alho-Richmond, P. Koskimies, N. Johansson, K. Huhtinen, K. Vihko, and K. Wähälä Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core J. Med. Chem. 52 21 2009 6660 6671
95. S. Karkola, A. Lilienkampf, and K. Wähälä A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking ChemMedChem 3 3 2008 461 472
96. M. Frotscher, E. Ziegler, S. Marchais-Oberwinkler, P. Kruchten, A. Neugebauer, L. Fetzer, C. Scherer, U. Müller-Vieira, J. Messinger, H. Thole, and R.W. Hartmann Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 51 7 2008 2158 2169 (Pubitemid 351503271)
97. S. Marchais-Oberwinkler, M. Frotscher, E. Ziegler, R. Werth, P. Kruchten, J. Messinger, H. Thole, and R.W. Hartmann Structure-activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors Mol. Cell. Endocrinol. 301 1-2 2009 205 211
98. S. Marchais-Oberwinkler, P. Kruchten, M. Frotscher, E. Ziegler, A. Neugebauer, U. Bhoga, E. Bey, U. Müller-Vieira, J. Messinger, H. Thole, and R.W. Hartmann Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics J. Med. Chem. 51 15 2008 4685 4698
99. E. Bey, S. Marchais-Oberwinkler, P. Kruchten, M. Frotscher, R. Werth, A. Oster, O. Algül, A. Neugebauer, and R.W. Hartmann Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases Bioorg. Med. Chem. 16 12 2008 6423 6435 (Pubitemid 351783414)
100. E. Bey, S. Marchais-Oberwinkler, R. Werth, M. Negri, Y.A. Al-Soud, P. Kruchten, A. Oster, M. Frotscher, B. Birk, and R.W. Hartmann Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) J. Med. Chem. 51 21 2008 6725 6739
101. Y.A. Al-Soud, E. Bey, A. Oster, S. Marchais-Oberwinkler, R. Werth, P. Kruchten, M. Frotscher, and R.W. Hartmann The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1 and type 2 Mol. Cell. Endocrinol. 301 1-2 2009 212 215
102. J. Gasteiger, X. Li, C. Rudolph, J. Sadowski, and J. Zupan Representation of molecular electrostatic potentials by topological feature maps J. Am. Chem. Soc. 116 1994 4608 4620 (Pubitemid 24981033)
103. A. Oster, T. Klein, R. Werth, P. Kruchten, E. Bey, M. Negri, S. Marchais-Oberwinkler, M. Frotscher, and R.W. Hartmann Novel estrone mimetics with high 17β-HSD1 inhibitory activity Bioorg. Med. Chem. 18 2010 3494 3505
104. P. Kruchten, R. Werth, S. Marchais-Oberwinkler, E. Bey, E. Ziegler, A. Oster, M. Frotscher, and R.W. Hartmann Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations C. R. Chim. 12 10-11 2009 1110 1116
105. N. Vicker, C.M. Sharland, W.B. Heaton, A.M. Ramos Gonzalez, H.V. Bailey, A. Smith, J.S. Springall, J.M. Day, H.J. Tutill, M.J. Reed, A. Purohit, and B.V.L. Potter The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors Mol. Cell. Endocrinol. 301 1-2 2009 259 265
106. K. Harada, H. Kubo, Y. Tomigahara, K. Nishioka, J. Takahashi, M. Momose, S. Inoue, and A. Kojima Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer Bioorg. Med. Chem. Lett. 20 1 2010 272 275
107. Y. Zhao, Y.S. Tan, S.Z. Haslam, and C. Yang Perfluorooctanoic acid effects on steroid hormone and growth factor levels mediate stimulation of peripubertal mammary gland development in C57BL/6 mice Toxicol. Sci. 115 1 2010 214 224
108. D. Poirier, P. Bydal, M.R. Tremblay, K.M. Sam, and V. Luu-The Inhibitors of type II 17beta-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 171 1-2 2001 119 128
109. P. Bydal, V. Luu-The, F. Labrie, and D. Poirier Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities Eur. J. Med. Chem. 44 2 2009 632 644
110. A. Kakefuda, Y. Kondoh, M. Hirano, A. Kamikawa, K. Enjo, T. Furutani, Benzimidazole derivatives, WO2009/014150 (2009).
111. T. Niimi, A. Kamikawa, Y. Amano, T. Yamaguchi, K. Suzumura, K. Enjo, T. Furutani, A. Kakefuda, Y. Kondoh, M. Hirano, 17beta-HSD type 5 inhibitor, US2009/0181960 (2009).
112. E. Bellevance, V. Luu-The, and D. Poirier Potent and selective steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone J. Med. Chem. 52 2009 7488 7502
113. H. Jokela, P. Rantakari, T. Lamminen, L. Strauss, R. Ola, A.L. Mutka, H. Gylling, T. Miettinen, P. Pakarinen, K. Sainio, and M. Poutanen Hydroxysteroid (17beta) dehydrogenase 7 activity is essential for fetal de novo cholesterol synthesis and for neuroectodermal survival and cardiovascular differentiation in early mouse embryos Endocrinology 151 4 2010 1884 1892
114. P. Rantakari, H. Lagerbohm, M. Kaimainen, J.P. Suomela, L. Strauss, K. Sainio, P. Pakarinen, and M. Poutanen Hydroxysteroid (17{beta}) dehydrogenase 12 is essential for mouse organogenesis and embryonic survival Endocrinology 151 4 2010 1893 1901
115. B. Husen, K. Huhtinen, M. Poutanen, L. Kangas, J. Messinger, and H. Thole Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme Mol. Cell. Endocrinol. 248 1-2 2006 109 113
116. B. Husen, K. Huhtinen, T. Saloniemi, J. Messinger, H.H. Thole, and M. Poutanen Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts Endocrinology 147 11 2006 5333 5339 (Pubitemid 44790588)
117. J. Messinger, L. Hirvelä, B. Husen, L. Kangas, P. Koskimies, O. Pentikainen, P. Saarenketo, and H. Thole New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 Mol. Cell. Endocrinol. 248 1-2 2006 192 198
118. J.M. Day, P.A. Foster, H.J. Tutill, M.F. Parsons, S.P. Newman, S.K. Chander, G.M. Allan, H.R. Lawrence, N. Vicker, B.V. Potter, M.J. Reed, and A. Purohit 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer Int. J. Cancer 122 9 2008 1931 1940 (Pubitemid 351441181)
119. R. Grümmer, F. Schwarzer, K. Bainczyk, H. Hess-Stumpp, P.A. Regidor, A.E. Schindler, and E. Winterhager Peritoneal endometriosis: validation of an in-vivo model Hum. Reprod. 16 8 2001 1736 1743 (Pubitemid 32761762)
120. S. Firnhaber, Expression und Regulation von Enzymen des Östrogenmetabolismus in humanen Endometriumläsionen kultiviert in der Nacktmaus, PhD-thesis, Universität Duisburg-Essen, Essen Fachbereich Biologie und Geographie, 2006.
121. T. Lamminen, T. Saloniemi, K. Huhtinen, P. Koskimies, J. Messinger, B. Husen, H. Thole, and M. Poutanen In vivo mouse model for analysis of hydroxysteroid (17beta) dehydrogenase 1 inhibitors Mol. Cell. Endocrinol. 301 1-2 2009 158 162
122. A. Einspanier, K. Lieder, A. Bruns, B. Husen, H. Thole, and C. Simon Induction of endometriosis in the marmoset monkey (Callithrix jacchus) Mol. Hum. Reprod. 12 5 2006 291 299 (Pubitemid 43821792)
123. P. Rantakari, L. Strauss, R. Kiviranta, H. Lagerbohm, J. Paviala, I. Holopainen, S. Vainio, P. Pakarinen, and M. Poutanen Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene Mol. Endocrinol. 22 3 2008 665 675 (Pubitemid 351397793)
124. Z. Shen, Z. Peng, Y. Sun, H.K. Vaananen, and M. Poutanen Overexpression of human hydroxysteroid (17beta) dehydrogenase 2 induces disturbance in skeletal development in young male mice J. Bone Miner. Res. 23 8 2008 1217 1226 (Pubitemid 352040177)
125. J.M. Day, H.J. Tutill, P.A. Foster, H.V. Bailey, W.B. Heaton, C.M. Sharland, N. Vicker, B.V. Potter, A. Purohit, and M.J. Reed Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 Mol. Cell. Endocrinol. 301 1-2 2009 251 258
126. S. Du Yan, Y. Zhu, E.D. Stern, Y.C. Hwang, O. Hori, S. Ogawa, M.P. Frosch, E.S. Connolly Jr., R. McTaggert, D.J. Pinsky, S. Clarke, D.M. Stern, and R. Ramasamy Amyloid beta-peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress J. Biol. Chem. 275 35 2000 27100 27109
127. K. Katoh, K. Kuma, H. Toh, and T. Miyata MAFFT version 5: improvement in accuracy of multiple sequence alignment Nucleic Acids Res. 33 2 2005 511 518 (Pubitemid 40360980)
128. A.M. Waterhouse, J.B. Procter, D.M. Martin, M. Clamp, and G.J. Barton Jalview Version 2 - a multiple sequence alignment editor and analysis workbench Bioinformatics 25 9 2009 1189 1191
129. P. Vihko, A. Herrala, P. Härkönen, V. Isomaa, H. Kaija, R. Kurkela, and A. Pulkka Control of cell proliferation by steroids: the role of 17HSDs Mol. Cell. Endocrinol. 248 1-2 2006 141 148
130. P. Vihko, A. Herrala, P. Härkönen, V. Isomaa, H. Kaija, R. Kurkela, Y. Li, L. Patrikainen, A. Pulkka, P. Soronen, and S. Törn Enzymes as modulators in malignant transformation J. Steroid Biochem. Mol. Biol. 93 2-5 2005 277 283 (Pubitemid 40602501)
131. W. Geissler, D. Davis, L. Wu, K. Bradshaw, S. Patel, B. Mendonca, K. Elliston, J. Wilson, D. Russell, and S. Andersson Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3 Nat. Genet. 7 1994 34 39
132. K.K. Rasiah, M. Gardiner-Garden, E.J. Padilla, G. Möller, J.G. Kench, M.C. Alles, S.A. Eggleton, P.D. Stricker, J. Adamski, R.L. Sutherland, S.M. Henshall, and V.M. Hayes HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer Mol. Cell. Endocrinol. 301 1-2 2009 89 96
133. Y. Jin, and T.M. Penning Aldo-keto reductases and bioactivation/ detoxication Annu. Rev. Pharmacol. Toxicol. 47 2006 263 292
134. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, P.G. Febbo, and S.P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 66 5 2006 2815 2825
135. M.G. Biswas, and D.W. Russell Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate J. Biol. Chem. 272 25 1997 15959 15966 (Pubitemid 27265577)
136. B.P. Haynes, A.H. Straume, J. Geisler, R. A'Hern, H. Helle, I.E. Smith, P.E. Lønning, and M. Dowsett Intratumoral estrogen disposition in breast cancer Clin. Cancer Res. 16 6 2010 1790 1801
137. J. Fomitcheva, M.E. Baker, E. Anderson, G.Y. Lee, and N. Aziz Characterization of Ke 6, a new 17beta-hydroxysteroid dehydrogenase, and its expression in gonadal tissues J. Biol. Chem. 273 35 1998 22664 22671 (Pubitemid 28399837)
138. M.M. Maxwell, J. Nearing, and N. Aziz Ke 6 gene. Sequence and organization and aberrant regulation in murine polycystic kidney disease J. Biol. Chem. 270 42 1995 25213 25219
139. J. Su, M. Lin, and J.L. Napoli Complementary deoxyribonucleic acid cloning and enzymatic characterization of a novel 17beta/3alpha-hydroxysteroid/ retinoid short chain dehydrogenase/reductase Endocrinology 140 11 1999 5275 5284
140. G. Froyen, M. Corbett, J. Vandewalle, I. Jarvela, O. Lawrence, C. Meldrum, M. Bauters, K. Govaerts, L. Vandeleur, H. Van Esch, J. Chelly, D. Sanlaville, H. van Bokhoven, H.H. Ropers, F. Laumonnier, E. Ranieri, C.E. Schwartz, F. Abidi, P.S. Tarpey, P.A. Futreal, A. Whibley, F.L. Raymond, M.R. Stratton, J.P. Fryns, R. Scott, M. Peippo, M. Sipponen, M. Partington, D. Mowat, M. Field, A. Hackett, P. Marynen, G. Turner, and J. Gécz Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardation Am. J. Hum. Genet. 82 2 2008 432 443
141. S.Y. Yang, X.Y. He, and D. Miller HSD17B10: a gene involved in cognitive function through metabolism of isoleucine and neuroactive steroids Mol. Genet. Metab. 92 1-2 2007 36 42 (Pubitemid 47361893)
142. P. Brereton, T. Suzuki, H. Sasano, K. Li, C. Duarte, V. Obeyesekere, F. Haeseleer, K. Palczewski, I. Smith, P. Komesaroff, and Z. Krozowski Pan1b (17betaHSD11)-enzymatic activity and distribution in the lung Mol. Cell. Endocrinol. 171 1-2 2001 111 117 (Pubitemid 32098205)
143. V. Luu-The, P. Tremblay, and F. Labrie Characterization of type 12 17beta-hydroxysteroid dehydrogenase (17beta-HSD12), an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women Mol. Endocrinol. 20 2 2006 437 443 (Pubitemid 43152516)
144. Y. Horiguchi, M. Araki, and K. Motojima 17beta-hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein Biochem. Biophys. Res. Commun. 370 2 2008 235 238
145. A.K. Jansson, C. Gunnarsson, M. Cohen, T. Sivik, and O. Stl 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer Cancer Res. 66 23 2006 11471 11477 (Pubitemid 46009980)